Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Sangamo Biosciences (SGMO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 208,340
  • Shares Outstanding, K 70,620
  • Annual Sales, $ 39,540 K
  • Annual Income, $ -40,700 K
  • 36-Month Beta 3.28
  • Price/Sales 4.82
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.65 +20.75%
on 12/08/16
4.60 -30.43%
on 11/14/16
-0.75 (-18.99%)
since 11/09/16
3-Month
2.65 +20.75%
on 12/08/16
5.06 -36.76%
on 09/28/16
-1.16 (-26.61%)
since 09/09/16
52-Week
2.65 +20.75%
on 12/08/16
9.83 -67.45%
on 12/18/15
-6.15 (-65.78%)
since 12/09/15

Most Recent Stories

More News
Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies...

Biotech Stocks on Investors' Radar -- Inovio Pharma, Pacific Biosciences of California, BioCryst Pharma, and Sangamo Biosciences

In today's pre-market research, Stock-Callers.com reviews the performances of four Biotech equities at the close: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Pacific Biosciences of California Inc. (NASDAQ:...

Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate...

Downgrade Alert for Sangamo Biosciences (SGMO)

Sangamo Biosciences (NASDAQ:SGMO) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $3.65 on volume of 1.0 million shares, above average daily volume of 770,000....

Sangamo BioSciences Reports Third Quarter 2016 Financial Results

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its third quarter 2016 financial results and provided an update on recent events and development timelines...

Downgrade Alert for Sangamo Biosciences (SGMO)

Sangamo Biosciences (NASDAQ:SGMO) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $3.60 on volume of 1.6 million shares, above average daily volume of 770,000....

Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast

Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that the company will release its third quarter 2016 financial results after the market closes on Wednesday,...

Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that members of the Company's research and development team will participate in the following scientific...

Biotech Stocks on Investors' Radar -- Arena Pharma, Progenics Pharma, Sangamo Biosciences, and Alnylam Pharma

As the US markets see some broader gains in yesterday's session, with five out of nine sectors ending in positive, Stock-Callers.com review the following Biotech stocks: Arena Pharmaceuticals Inc. (NASDAQ:...

Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Sangamo BioSciences, Inc. is a leader in the development of noveltranscription factors for the regulation of gene expression. Transcriptionfactors are proteins that turn genes on or off by recognizing specific DNAsequences. The Universal Gene Recognition technology platform enables theengineering of...

See More

Support & Resistance

2nd Resistance Point 3.73
1st Resistance Point 3.47
Last Price 3.20
1st Support Level 2.82
2nd Support Level 2.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.